July 13, 2014 2:44 AM ET

Healthcare Providers and Services

Company Overview of Mytrus, Inc.

Company Overview

Mytrus, Inc. provides services to connect pharmaceutical, biotechnology, medical device, and healthcare advocacy groups directly with patients for their clinical trials. It enables people to safely participate in clinical trials from their home. The company was incorporated in 2009 and is based in San Francisco, California.

350 Sansome Street

Suite 815

San Francisco, CA 94104

United States

Founded in 2009





Key Executives for Mytrus, Inc.

Chief Executive Officer and Member of Innovation Advisory Board
President and Director
Senior Vice President of Clinical Affairs and Senior Medical Director
Compensation as of Fiscal Year 2014.

Mytrus, Inc. Key Developments

Mytrus, Inc. Creates New Innovation Advisory Board

Mytrus, Inc. announced the creation of a new Innovation Advisory Board comprised of industry experts who will help shape the future of clinical products and services offered by the company. The six Innovation Advisory Board members include: Steven Cummings, MD is co-founder of Mytrus and an expert in the design and implementation of clinical research studies. Dr. Cummings, the Chief Scientific Officer at Mytrus, also serves as Director of the San Francisco Coordinating Center, Emeritus Professor of Medicine, Epidemiology and Biostatistics at UCSF and Senior Scientist at CPMC Research Institute and Innovator-in-Residence at Roche-Genentech. David G. Forster, JD, MA, CIP, Chief Compliance Officer, WIRB-Copernicus Group joined the Western Institutional Review Board in 1996 and currently serves as Chief Compliance Officer as well as a co-chair on a subcommittee of the Health and Human Services Secretary's Advisory Committee on Human Research Protections. Clay Johnston, MD, PhD is Dean of Medicine at the new University of Texas Dell Medical School in Austin. Dr. Johnston recently served as Director of the Clinical Translational Sciences Institute at the University of California, San Francisco, and an expert in clinical trial methods. Garry Neil, MD is Global Head of Research and Development at Medgenics and a leader in clinical trials innovation. At Johnson & Johnson, he served as Corporate Vice President of Science & Technology and Group President of Pharmaceutical Research and Development. Dr. Neil also is a Founder/Director and served as CEO of TransCelerate Biopharma Inc. Dr. John Orloff, MD is Global Head of Clinical Development at Merck Serono. Dr. Orloff recently served as Chief Medical Officer and Senior Vice President, Global Development for Novartis Pharma AG where he led the 'Trials of the Future' initiative to bring innovation to the drug development process. He also served as Head of U.S. Medical and Drug Regulatory Affairs for North America. Jane Perlmutter, PhD, MBA is a psychologist and leading patient advocate for clinical trial participants. Dr. Perlumutter also serves on the Clinical Trials Transformation Initiative on Informed Consent.

University of Alabama at Birmingham to Enroll Patients in Pilot Study Using Mytrus, Inc.'s iPad Application

Mytrus, Inc. announced that the University of Alabama at Birmingham will use its iPad application in an upcoming pilot study supported by the U.S. Department of Health & Human Services Agency for Healthcare Research and Quality. UAB is evaluating how digital tools might simplify enrollment and enhance patient understanding during the informed consent process. Kenneth G. Saag, MD, Msc, professor in the UAB Department of Medicine, will lead the study. Using animation and other visual imagery, the company iPad application is the first to condense the complex and critical disclosure information required at the start of a clinical trial into an easy-to-understand, digitized format. This new approach not only helps patients better understand the clinical trial process; it helps researchers gain valuable insight into the speed and effectiveness of the informed consent process in multi-center studies.

Mytrus, Inc. Announces its iPad(R) Application to Be Used in a Global, Multi-Year Study Supported by the National Institute of Neurological Disorders and Stroke

Mytrus, Inc. announced that its iPad(R) application explaining informed consent prior to clinical trial patient enrollment has been selected for use in a global, multi-year study supported by The National Institute of Neurological Disorders and Stroke. Led by researchers from the University of California, San Francisco Stroke Sciences Group, the five-year POINT clinical trial involves 4,150 patients in 120 clinical test sites in every region of the globe. A number of NINDS Neurological Emergencies Treatment Trials Network clinical site hubs are participating, supplemented and supported by sites through the NETT Clinical Coordinating Center at the University of Michigan.

Similar Private Companies By Industry

Company Name Region
PracticeWares, Inc. United States
MDVIP, Inc. United States
Concept Rehab, Inc. United States
Sleep Medicine Institute Management, LLC United States
TriCore Reference Laboratories United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Mytrus, Inc., please visit www.mytrus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.